Empyrean Neuroscience

Executive Summary

Empyrean Neuroscience, a UK-based biotechnology company founded in 2021, is pioneering a novel platform that genetically engineers fungi and plants to produce potentiated neuroactive small molecule compounds. Leveraging this proprietary biosynthesis approach, the company aims to develop first-in-class therapeutics for neurological and neuropsychiatric disorders with significant unmet needs, including depression, PTSD, substance abuse disorders, and chronic pain. By harnessing natural systems to generate complex molecules, Empyrean seeks to overcome traditional synthetic chemistry limitations, potentially yielding compounds with improved efficacy, selectivity, and tolerability. The platform's ability to produce diverse neuroactive scaffolds positions the company to build a broad pipeline targeting multiple CNS indications. The company's strategy addresses a critical gap in CNS drug development, where high attrition rates and limited innovation have left many patients without adequate treatment options. Empyrean's approach could unlock new chemical space and accelerate the discovery of safer, more effective therapies. While still in early preclinical stages, the platform has the potential to disrupt the CNS therapeutic landscape. Success in initial proof-of-concept studies could attract significant partnership or funding interest. Empyrean represents a high-risk, high-reward opportunity in the neurotherapeutics space, with its value inflection tied to future pipeline milestones and validation of its synthetic biology platform.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Nomination for Depression or PTSD40% success
• Q1 2027Series A Financing to Advance Platform and Pipeline60% success
• Q2 2027Preclinical Proof-of-Concept Data in Animal Models50% success